Education and decision support. This release does not generate doses, injection instructions, cycles, diagnoses, prescriptions, or vendor pathways.
What it is
Activates GIP and GLP-1 receptors, influencing appetite, glucose-dependent insulin signaling, and energy intake.
FDA approved for defined indicationsMetabolic
Tirzepatide
A dual GIP/GLP-1 therapy with product-specific FDA indications and substantial human evidence.
Worth comparing
ReceptorknownRoutessubcutaneousConfidencehigh
Visible for broad education until a goal is selected.
FDA approved for defined indications.
Useful for
Comparing evidence-backed medical weight-management options
Preparing for a prescribing consultation
Not established for
Use without medical screening
Combining with another GLP-1 product without prescriber direction
Evidence receipts
FDA approved claimReviewed 2026-07-12
Chronic weight management
FDA-approved tirzepatide products include an indication for long-term weight reduction in defined adults when combined with reduced-calorie diet and physical activity.
Approval is product- and indication-specific; candidacy and contraindications require a prescriber.
